Immune Escape Mechanisms in Diffuse Larce B-Cell Lymphoma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F12%3A33141574" target="_blank" >RIV/61989592:15110/12:33141574 - isvavai.cz</a>

Result on the web

<a href="http://www.hindawi.com/isrn/immunology/2012/208903/" target="_blank" >http://www.hindawi.com/isrn/immunology/2012/208903/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5402/2012/208903" target="_blank" >10.5402/2012/208903</a>

Result language

angličtina

Original language name

Immune Escape Mechanisms in Diffuse Larce B-Cell Lymphoma

Original language description

Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of non-Hodgkin lymphomas in Western countries. Implementation of immunotherapy using monoclonal antibodies to therapeutic protocols has led to dramatic improvements in overall survival. DLBCL became a model of a successful immunochemotherapy concept. Despite this fact, there is still a proportion of patients who do not respond to or relapse early after treatment. Growing evidence suggests that host antitumor immunity is suppressed by lymphoma cells in many ways. First, host cytotoxic T cells are directly suppressed by interaction with programmed cell death (PD) ligand on lymphoma cell surface and a similar mechanism enhances the activity of suppressive regulatory T cells (Tregs). Second, tumor cells escape host cytotoxic cells due to lower immunogenicity caused by reduced expression of HLA antigens. Both mechanisms have an origin in primary genetic events in lymphomagenesis. Rearrangement of MHC class II transcriptional

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NT11103" target="_blank" >NT11103: The analysis of molecular subtypes of diffuse large B-cell lymphoma by high-resolution arrayCGH for determination of genetic changes of prognostic importance</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)<br>S - Specificky vyzkum na vysokych skolach

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

ISRN Immunology

ISSN

2090-5645

e-ISSN

—

Volume of the periodical

2012

Issue of the periodical within the volume

208903

Country of publishing house

US - UNITED STATES

Number of pages

6

Pages from-to

1-6

UT code for WoS article

—

EID of the result in the Scopus database

—